Fonar enters Nasdaq good graces

Article

Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted.

Fonar enters Nasdaq good graces
Dedicated MR vendor Fonar is in compliance with the Nasdaq stock exchange, ending concerns that the company would be delisted. At issue was whether Fonar satisfied Nasdaq Listing Rule 5550(b)(3), which requires companies on the exchange to have a minimum $500,000 of net income from continuing operations in the latest fiscal year. Fonar’s most recent Form 10-K, filed Oct. 5, showed net income from continuing operations of $1.1 million for the fiscal year ended June 30, 2009.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.